Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357826 | 1.00 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL5359103 | 0.99 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL5353425 | 0.95 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL5349647 | 0.91 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL5351982 | 0.90 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL6430444 | 0.88 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL4671481 | 0.87 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL3188702 | 0.86 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL3970054 | 0.86 | TLR7 (0.78) | TLR7TLR8 | |
| SCHEMBL5349297 | 0.85 | TLR7 (0.77) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1541572-A1 | Thioether substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1341791-B1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2005-05-25 | — | — | EP | claimed |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-27 | — | — | US | claimed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | claimed |
| US-6664264-B2 | Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | claimed |
| EP-1341791-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | claimed |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | claimed |
| WO-2002046192-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | claimed |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | disclosed |
| US-20170319712-A1 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-11-09 | — | — | US | disclosed |
| US-9801947-B2 | Methods and compositions for enhancing immune response | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3001990-A1 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-1765310-B1 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2015-10-28 | — | — | EP | disclosed |
| US-6664264-B2 | Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| EP-1341791-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003050121-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002046192-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20170319712-A1 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | LRBA, CD69, MYD88 | TLR7 59/4885TLR8 60/4885 |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR7 2/4885TLR8 3/4885 |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 30/4885TLR8 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.